From a clinical perspective, in terms of median overall survival, the authors did not find any statistically significant difference between wild-type TP53/RB1 SCLC tumors and TP53/RB1-mutant SCLC tumors. This evidence concerns the gene TP53 and small cell lung carcinoma.